Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

STE vs MMSI vs HSIC vs NVCR vs HOLX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
STE
STERIS plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$21.00B
5Y Perf.+28.8%
MMSI
Merit Medical Systems, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$3.72B
5Y Perf.+38.5%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.09B
5Y Perf.+16.1%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%

STE vs MMSI vs HSIC vs NVCR vs HOLX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
STE logoSTE
MMSI logoMMSI
HSIC logoHSIC
NVCR logoNVCR
HOLX logoHOLX
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DistributionMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$21.00B$3.72B$8.09B$1.92B$16.97B
Revenue (TTM)$5.83B$1.54B$13.18B$674M$4.13B
Net Income (TTM)$708M$139M$398M$-173M$544M
Gross Margin44.1%48.7%29.1%75.2%52.8%
Operating Margin17.2%12.2%5.8%-27.2%17.5%
Forward P/E21.0x15.5x13.3x17.2x
Total Debt$2.20B$898M$3.69B$290M$2.63B
Cash & Equiv.$172M$449M$156M$103M$1.96B

STE vs MMSI vs HSIC vs NVCR vs HOLXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

STE
MMSI
HSIC
NVCR
HOLX
StockMay 20May 26Return
STERIS plc (STE)100128.8+28.8%
Merit Medical Syste… (MMSI)100138.5+38.5%
Henry Schein, Inc. (HSIC)100116.1+16.1%
NovoCure Limited (NVCR)10025.0-75.0%
Hologic, Inc. (HOLX)100142.6+42.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: STE vs MMSI vs HSIC vs NVCR vs HOLX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. STERIS plc is the stronger pick specifically for dividend income and shareholder returns and operational efficiency and capital deployment. MMSI and HSIC also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
STE
STERIS plc
The Income Pick

STE is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 14 yrs, beta 0.69, yield 1.0%
  • 220.0% 10Y total return vs HOLX's 124.3%
  • PEG 3.86 vs HSIC's 4.21
  • 1.0% yield; 14-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability and long-term compounding
MMSI
Merit Medical Systems, Inc.
The Growth Play

MMSI ranks third and is worth considering specifically for growth exposure.

  • Rev growth 11.7%, EPS growth 4.9%, 3Y rev CAGR 9.6%
  • 11.7% revenue growth vs HOLX's 1.7%
Best for: growth exposure
HSIC
Henry Schein, Inc.
The Value Play

HSIC is the clearest fit if your priority is value.

  • Lower P/E (13.3x vs 17.2x)
Best for: value
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
HOLX
Hologic, Inc.
The Defensive Pick

HOLX carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • 13.2% margin vs NVCR's -25.7%
  • Beta 0.41 vs NVCR's 2.20, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthMMSI logoMMSI11.7% revenue growth vs HOLX's 1.7%
ValueHSIC logoHSICLower P/E (13.3x vs 17.2x)
Quality / MarginsHOLX logoHOLX13.2% margin vs NVCR's -25.7%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs NVCR's 2.20, lower leverage
DividendsSTE logoSTE1.0% yield; 14-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)HOLX logoHOLX+37.1% vs MMSI's -33.8%
Efficiency (ROA)STE logoSTE6.7% ROA vs NVCR's -16.5%, ROIC 7.2% vs -16.4%

STE vs MMSI vs HSIC vs NVCR vs HOLX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

STESTERIS plc
FY 2025
Product
52.6%$2.9B
Service
47.4%$2.6B
MMSIMerit Medical Systems, Inc.
FY 2025
Cardiovascular
95.2%$1.4B
Endoscopy
4.8%$73M
HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M
NVCRNovoCure Limited

Segment breakdown not available.

HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M

STE vs MMSI vs HSIC vs NVCR vs HOLX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSTELAGGINGNVCR

Income & Cash Flow (Last 12 Months)

HOLX leads this category, winning 3 of 6 comparable metrics.

HSIC is the larger business by revenue, generating $13.2B annually — 19.5x NVCR's $674M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
RevenueTrailing 12 months$5.8B$1.5B$13.2B$674M$4.1B
EBITDAEarnings before interest/tax$1.4B$290M$1.1B-$165M$974M
Net IncomeAfter-tax profit$708M$139M$398M-$173M$544M
Free Cash FlowCash after capex$917M$274M$561M-$48M$1000M
Gross MarginGross profit ÷ Revenue+44.1%+48.7%+29.1%+75.2%+52.8%
Operating MarginEBIT ÷ Revenue+17.2%+12.2%+5.8%-27.2%+17.5%
Net MarginNet income ÷ Revenue+12.1%+9.0%+3.0%-25.7%+13.2%
FCF MarginFCF ÷ Revenue+15.7%+17.8%+4.3%-7.1%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year+9.2%+7.8%+7.7%+12.3%+2.5%
EPS Growth (YoY)Latest quarter vs prior year+12.0%+38.8%+14.9%-100.0%-9.2%
HOLX leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

HSIC leads this category, winning 5 of 7 comparable metrics.

At 21.6x trailing earnings, HSIC trades at a 37% valuation discount to STE's 34.5x P/E. Adjusting for growth (PEG ratio), STE offers better value at 6.35x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Market CapShares × price$21.0B$3.7B$8.1B$1.9B$17.0B
Enterprise ValueMkt cap + debt − cash$23.0B$4.2B$11.6B$2.1B$17.6B
Trailing P/EPrice ÷ TTM EPS34.46x29.26x21.56x-13.80x30.53x
Forward P/EPrice ÷ next-FY EPS est.20.95x15.46x13.26x17.21x
PEG RatioP/E ÷ EPS growth rate6.35x6.84x
EV / EBITDAEnterprise value multiple17.15x13.06x10.87x17.39x
Price / SalesMarket cap ÷ Revenue3.85x2.45x0.61x2.92x4.14x
Price / BookPrice ÷ Book value/share3.20x2.38x1.79x5.51x3.43x
Price / FCFMarket cap ÷ FCF27.00x17.24x14.12x18.44x
HSIC leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

STE leads this category, winning 4 of 9 comparable metrics.

HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-51 for NVCR. STE carries lower financial leverage with a 0.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), STE scores 8/9 vs HSIC's 4/9, reflecting strong financial health.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
ROE (TTM)Return on equity+9.9%+8.9%+8.2%-50.8%+11.0%
ROA (TTM)Return on assets+6.7%+5.2%+3.6%-16.5%+6.1%
ROICReturn on invested capital+7.2%+7.2%+7.1%-16.4%+9.4%
ROCEReturn on capital employed+9.0%+7.9%+9.8%-28.9%+8.8%
Piotroski ScoreFundamental quality 0–986457
Debt / EquityFinancial leverage0.33x0.57x0.77x0.85x0.52x
Net DebtTotal debt minus cash$2.0B$450M$3.5B$187M$667M
Cash & Equiv.Liquid assets$172M$449M$156M$103M$2.0B
Total DebtShort + long-term debt$2.2B$898M$3.7B$290M$2.6B
Interest CoverageEBIT ÷ Interest expense15.94x10.74x4.59x-96.80x8.00x
STE leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

STE leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors STE at 5.3% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
YTD ReturnYear-to-date-14.3%-27.9%-8.2%+28.3%+1.9%
1-Year ReturnPast 12 months-3.9%-33.8%+5.9%+1.1%+37.1%
3-Year ReturnCumulative with dividends+16.6%-26.5%-11.7%-75.7%-8.5%
5-Year ReturnCumulative with dividends+5.9%-3.6%-12.5%-91.3%+15.8%
10-Year ReturnCumulative with dividends+220.0%+214.6%+5.3%+30.3%+124.3%
CAGR (3Y)Annualised 3-year return+5.3%-9.8%-4.0%-37.6%-2.9%
STE leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Beta (5Y)Sensitivity to S&P 5000.69x0.71x0.73x2.20x0.41x
52-Week HighHighest price in past year$269.44$100.19$89.29$20.06$76.04
52-Week LowLowest price in past year$204.81$59.74$61.95$9.82$52.81
% of 52W HighCurrent price vs 52-week peak+79.3%+62.2%+79.0%+83.9%+100.0%
RSI (14)Momentum oscillator 0–10041.234.939.169.869.1
Avg Volume (50D)Average daily shares traded710K769K1.2M1.5M10.0M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

STE leads this category, winning 1 of 1 comparable metric.

Analyst consensus: STE as "Buy", MMSI as "Buy", HSIC as "Hold", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79). STE is the only dividend payer here at 1.04% yield — a key consideration for income-focused portfolios.

MetricSTE logoSTESTERIS plcMMSI logoMMSIMerit Medical Sys…HSIC logoHSICHenry Schein, Inc.NVCR logoNVCRNovoCure LimitedHOLX logoHOLXHologic, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuyHold
Price TargetConsensus 12-month target$256.67$95.00$86.43$33.50$79.00
# AnalystsCovering analysts1313321542
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises141
Dividend / ShareAnnual DPS$2.22
Buyback YieldShare repurchases ÷ mkt cap+1.0%0.0%+10.5%0.0%+4.4%
STE leads this category, winning 1 of 1 comparable metric.
Key Takeaway

STE leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). HOLX leads in 2 (Income & Cash Flow, Risk & Volatility).

Best OverallSTERIS plc (STE)Leads 3 of 6 categories
Loading custom metrics...

STE vs MMSI vs HSIC vs NVCR vs HOLX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is STE or MMSI or HSIC or NVCR or HOLX a better buy right now?

For growth investors, Merit Medical Systems, Inc.

(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate STERIS plc (STE) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — STE or MMSI or HSIC or NVCR or HOLX?

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus STERIS plc at 34. 5x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: STERIS plc wins at 3. 86x versus Henry Schein, Inc. 's 4. 21x.

03

Which is the better long-term investment — STE or MMSI or HSIC or NVCR or HOLX?

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: STE returned +220. 0% versus HSIC's +5. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — STE or MMSI or HSIC or NVCR or HOLX?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, STERIS plc (STE) carries a lower debt/equity ratio of 33% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — STE or MMSI or HSIC or NVCR or HOLX?

By revenue growth (latest reported year), Merit Medical Systems, Inc.

(MMSI) is pulling ahead at 11. 7% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: STERIS plc grew EPS 62. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — STE or MMSI or HSIC or NVCR or HOLX?

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is STE or MMSI or HSIC or NVCR or HOLX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, STERIS plc (STE) is the more undervalued stock at a PEG of 3. 86x versus Henry Schein, Inc. 's 4. 21x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 3x forward P/E versus 21. 0x for STERIS plc — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — STE or MMSI or HSIC or NVCR or HOLX?

In this comparison, STE (1.

0% yield) pays a dividend. MMSI, HSIC, NVCR, HOLX do not pay a meaningful dividend and should not be held primarily for income.

09

Is STE or MMSI or HSIC or NVCR or HOLX better for a retirement portfolio?

For long-horizon retirement investors, STERIS plc (STE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

69), 1. 0% yield, +220. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STE: +220. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between STE and MMSI and HSIC and NVCR and HOLX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

STE pays a dividend while MMSI, HSIC, NVCR, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

STE

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

MMSI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform STE and MMSI and HSIC and NVCR and HOLX on the metrics below

Revenue Growth>
%
(STE: 9.2% · MMSI: 7.8%)
Net Margin>
%
(STE: 12.1% · MMSI: 9.0%)
P/E Ratio<
x
(STE: 34.5x · MMSI: 29.3x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.